April 17, 2018 04:00 PM EDT
R&D

Block­buster am­bi­tions: Am­gen/No­var­tis team lines up more promis­ing PhI­II erenum­ab da­ta for some of the tough­est mi­graine pa­tients

John Carroll

Editor & Founder

Am­gen $AMGN and its Big Phar­ma brethren at No­var­tis $NVS have lined up an­oth­er hap­py end­ing for the lat­est chap­ter on the mar­ket­ing pitch be­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times